Background: In patients with resected, stage II-III NSCLC, the 5-year disease-free survival (DFS) rate with SoC adjuvant chemotherapy is ~40%. Despite advances with immunotherapy (IO) in the metastatic setting, overall survival (OS) rates for patients with recurrence remain low. Detection of minimal residual disease (MRD), as indicated by circulating tumor DNA (ctDNA), may indicate the presence of clinically indiscernible residual tumor following curative-intent therapy and enable earlier therapeutic intervention, thereby improving outcomes in patients at highest risk of recurrence.
No takes yet. Share an insight, caveat, or question.
Spigel et al. (2021) studied this question.